Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Zevalin. Always confirm against the full prescribing information.
100 interactions
Acenocoumarol
The risk or severity of adverse effects can be increased when Acenocoumarol is combined with Ibritumomab tiuxetan.
Level 1 evidence
Acetylsalicylic acid
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ibritumomab tiuxetan.
Level 1 evidence
Allopurinol
The risk or severity of adverse effects can be increased when Allopurinol is combined with Ibritumomab tiuxetan.
Level 1 evidence
Anagrelide
The risk or severity of adverse effects can be increased when Anagrelide is combined with Ibritumomab tiuxetan.
Level 1 evidence
Anthrax immune globulin human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ibritumomab tiuxetan.
Level 2 evidence
Apixaban
The risk or severity of adverse effects can be increased when Apixaban is combined with Ibritumomab tiuxetan.
Level 1 evidence
Astaxanthin
The risk or severity of adverse effects can be increased when Astaxanthin is combined with Ibritumomab tiuxetan.
Level 1 evidence
AstraZeneca COVID-19 Vaccine
The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Ibritumomab tiuxetan.
Level 2 evidence
Betrixaban
The risk or severity of adverse effects can be increased when Betrixaban is combined with Ibritumomab tiuxetan.
The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.
Level 2 evidence
Brinase
The risk or severity of adverse effects can be increased when Brinase is combined with Ibritumomab tiuxetan.
Level 1 evidence
Cangrelor
The risk or severity of adverse effects can be increased when Cangrelor is combined with Ibritumomab tiuxetan.
Level 1 evidence
Enter your NPI to unlock 52 major interactions for Zevalin
Zevalin (Ibritumomab Tiuxetan) has 434 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Zevalin (Ibritumomab Tiuxetan) has 219 major, 74 moderate, and 141 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Zevalin. Always confirm against the full prescribing information.